Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
Blue Earth Therapeutics Ltd
University Health Network, Toronto
Wake Forest University Health Sciences
National Institutes of Health Clinical Center (CC)
Pathos AI, Inc.
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Cedars-Sinai Medical Center
K36 Therapeutics, Inc.
M.D. Anderson Cancer Center
Atavistik Bio, Inc
Varian, a Siemens Healthineers Company
M.D. Anderson Cancer Center
University of California, Davis
National Institutes of Health Clinical Center (CC)
University of California, Irvine
Washington University School of Medicine
Spanish Oncology Genito-Urinary Group
Indiana University
H. Lee Moffitt Cancer Center and Research Institute
DL Analytics
Centre Hospitalier Universitaire de Nīmes
National Institutes of Health Clinical Center (CC)
NanOlogy, LLC
Wake Forest University Health Sciences
Dana-Farber Cancer Institute
University Health Network, Toronto
AgonOx, Inc.
Memorial Sloan Kettering Cancer Center
Indiana University
RenJi Hospital
M.D. Anderson Cancer Center
Eli Lilly and Company
The Netherlands Cancer Institute
City of Hope Medical Center
Jinling Hospital, China
Queen Mary University of London
University of California, San Francisco
NiKang Therapeutics, Inc.
University of Washington
Johns Hopkins University
British Columbia Cancer Agency
University of Miami
The Netherlands Cancer Institute
Dana-Farber Cancer Institute
RefleXion Medical
Milton S. Hershey Medical Center